Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

MLA

Hui‐Jen Tsai, et al. “Phase I Study of ADI‐PEG20 plus Low‐dose Cytarabine for the Treatment of Acute Myeloid Leukemia.” Cancer Medicine, vol. 10, no. 9, May 2021, pp. 2946–55. EBSCOhost, https://doi.org/10.1002/cam4.3871.

APA

Hui‐Jen Tsai, Hui‐Hua Hsiao, Ya‐Ting Hsu, Yi‐Chang Liu, Hsiao‐Wen Kao, Ta‐Chih Liu, Shih‐Feng Cho, Xiaoxing Feng, Amanda Johnston, John S. Bomalaski, Ming‐Chung Kuo, & Tsai‐Yun Chen. (2021). Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia. Cancer Medicine, 10(9), 2946–2955. https://doi.org/10.1002/cam4.3871

Chicago

Hui‐Jen Tsai, Hui‐Hua Hsiao, Ya‐Ting Hsu, Yi‐Chang Liu, Hsiao‐Wen Kao, Ta‐Chih Liu, Shih‐Feng Cho, et al. 2021. “Phase I Study of ADI‐PEG20 plus Low‐dose Cytarabine for the Treatment of Acute Myeloid Leukemia.” Cancer Medicine 10 (9): 2946–55. doi:10.1002/cam4.3871.